Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
Reading miRNAs for Clinical Meaning
Single miRNAs Don’t Say Much, but They May Become Eloquent Biomarkers if We Take Their Testimony in Context
Sorting Out the CRISPR Patent Case
Sounds of Science Podcast
Good Assays for Bad Immunogenicity
Avoid “Bad” Immunogenicity by Using Assays That Are More Sensitive and Can Adapt to Increasingly Complex and Specialized Drugs
For full access to this article login to GEN Select now.
Investigating and Focusing on Ion Channels as Drug Targets
New Screening Methods Could Increase the Utility of These Abundant Proteins
- Arthur Brown, M.D., Ph.D., president and CEO of ChanTest, summed up the sentiments of a number of speakers at the recent “SBS Conference” in Lille, France, when he said, “Ion channels are as abundant as GPCRs in the known druggable genome and have as much potential as drug targets ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.